Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Next-generation heart bypass grafts to naturally restore cardiovascular function. (HeartRestore)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Netherlands,Switzerland
Call: EIC Accelerator Open 2021 (HORIZON-EIC-2021-ACCELERATOROPEN-01, 2021)
Start date: 2022-12-01
End date: 2025-11-30
Duration (months): 36.0
Total project cost (EUR): 4205283.5
EU funding (EUR): 2481701.0
Participants: 2
Project status: SIGNED

Coronary Artery Disease is caused by narrowing of heart arteries that supply blood, often due to atherosclerosis. Coronary artery bypass grafting (CABG) is the gold standard surgery to treat it, and it commonly involves harvesting patient’s veins from the legs as grafts. This collection affects patients causing chronic pain and costly complications. It also has a high failure rate with >20% implants occluded after 1 year. Xeltis has developed a unique restorative vascular graft (XABG) that eliminates the need for vein harvesting. The implant provides a homing structure for cells in which cardiac and vascular tissues can be naturally restored, with the related advantages and benefits for patients and the healthcare system. We have proven our technology in first niche applications, as well as completed pre-clinical studies successfully for XABG. Now, we plan to perform a full clinical validation to obtain a CE mark in Europe and start market deployment and commercial up-scaling.

Keywords: coronary artery disease,cardiovascular tissue restoration,synthetic cardiac implants,bioabsorbable medical devices
INTEGRATED PHOTONICS FOR SIGNAL PROCESSING AND LASERS TOWARDS THE NEXT GENERATION OPTICAL COHERENCE TOMOGRAPHY (INTEGRAL)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Ireland,United Kingdom,Italy
Call: EIC Pathfinder Open (HORIZON-EIC-2025-PATHFINDEROPEN, 2025)
Start date: 2026-03-01
End date: 2029-02-28
Duration (months): 36.0
Total project cost (EUR): 2999500.0
EU funding (EUR): 2999500.0
Participants: 4
Project status: SIGNED

Optical Coherence Tomography (OCT) is a powerful and scalable imaging platform, indispensable in ophthalmology and increasingly relevant in dermatology, cardiology, and industrial inspection. Yet its broader potential remains constrained by the lack of real-time en-face visualization and reliance on bulky, high-cost hardware. INTEGRAL addresses these challenges by rethinking OCT architecture from source to signal, introducing integrated photonic technologies that eliminate long-standing bottlenecks. At its core are two breakthrough innovations: a Down-conversion Leader-Follower (DLF) photonic processor that performs direct optical-domain signal processing without FFT or resampling, and an Akinetic Dispersive Laser (ADL) providing fast, stable, compact swept-source illumination with no moving parts. Implemented as photonic integrated circuits, these components enable real-time, multi-depth en-face imaging at sweep rates beyond 5 MHz—an order of magnitude faster than today’s commercial systems. INTEGRAL targets two key OCT wavelength bands—1060nm for deep tissue penetration and 840nm for high-resolution imaging—delivering a compact, modular engine compatible with current and next-gen systems. By eliminating the need for highspeed digitization and enabling instant visual feedback, INTEGRAL unlocks new applications across ophthalmology, surgery, dermatology & industrial inspection. The project brings together world-leading expertise in photonic integration, OCT, and medical device manufacturing in a high-risk, high-gain initiative that aims to rewrite the technological foundations of medical imaging. If successful, INTEGRAL will enable widespread OCT adoption not just in clinics, but also in general practices, pharmacies, and even homes—supporting accessible health monitoring. This lays a strong foundation for post-project commercial exploitation and TRL scaling, establishing a sovereign EU supply chain and leadership in a high-value, fast-growing global market.

Keywords: lasers,photonics,oct biomedical,tunable lasers
2D Non-van der Waals Bimetallic Transition Metal Chalcogenides for Magnesium-Ion Energy Storage (BiM-ION)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Czechia,Greece
Call: ERA Fellowships (HORIZON-WIDERA-2023-TALENTS-02, 2023)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 150438.72
EU funding (EUR): 150438.72
Participants: 2
Project status: SIGNED

Magnesium-ion batteries (MIBs) present compelling performance and sustainability attributes, while sharing common manufacturing techniques with lithium-ion batteries, thus enabling rapid commercialization. However, challenges remain to be addressed, such as low capacity and poor cycling stability of the cathode materials stemming from sluggish Mg2+ diffusion kinetics, dendrite growth and irreversible Mg plating/stripping of the Mg metal anode, especially when operating in non-corrosive electrolytes. In response to these challenges, BiM-ION project leverages the expanding toolbox of 2D non-van der Waals (nvdW) bimetallic transition metal chalcogenides (BTMCs) and hybrids thereof with functionalized conductive graphene derivatives as potential cathode materials for MIBs. The 2D engineered nvdW BTMCs will be utilized to boost the Mg-ion diffusion and by leveraging metal-metal cooperativity in these structures BiM-ION aims to ascribe stable redox cycles and boost the stored energy. Importantly, tailored graphene derivatives with dense out-of-plane functionalities can facilitate the formation of covalent hybrids with 2D nvdW BTMCs, ascribing improved charge transport and stability of the resulting heterostructured electrodes, ultimately enabling long-term cyclability of MIBs. The Mg metal anode will be engineered by applying heteroatom doped graphene structures adorned with single metal atoms at the surface to improve the Mg-nucleation, and magnesiophilicity, to impede the irreversible Mg plating/stripping in non-corrosive electrolytes. The BiM-ION project aims to revolutionizing energy storage based on safer, abundant, environmentally friendly, and cost-effective solutions, thereby reducing our reliance on lithium-based technologies and accelerate the transition to sustainable energy sources.

Keywords: two dimension,non van der waals,bimetallic transition metal chalcogenides,conductive graphene,hybrids,magnesium ion batteries,sustainable
Building the industrial metaverse by humanising data through intelligent, cost-effective and scalable platform for digital twins (SEKAI)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Malta
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Modern industries, despite significant advancements over the past decades, still grapple with notable inefficiencies that hinder their full potential. Industry 5.0 aims to address these inefficiencies by promoting collaboration between humans and advanced technologies. There is a common consensus that digital twins are the fundamental drivers of the required transformation to Industry 5.0, as they act as catalysts for greater resource efficiency and sustainability. They also enable networked collaboration through data interoperability and the use of AI. Traditional digital twin technologies, however, face significant challenges, including high costs, complexity, and limited autonomy for users. These limitations often result in data silos and fragmented systems, hindering real-time decision-making and seamless integration. As industries strive to transition to Industry 5.0, there is an urgent need for advanced, user-friendly tools that empower businesses to create and manage digital twins with minimal software expertise. The SEKAI platform addresses these challenges by offering a cutting-edge Software Development Kit (SDK) that enables customers to build sophisticated digital twins autonomously. Our solution leverages the latest advancements in artificial intelligence (AI) and WEB3 technologies, providing a scalable, efficient, and precise operational toolset. By integrating these technologies, SEKAI ensures that customers can independently develop and customize their digital twins, thereby reducing reliance on external modifications and support. The current SEKAI platform, while robust, does not yet offer complete autonomy for customers to create and manage their logic patterns and data connections. To advance to Technology Readiness Levels (TRL) 7 and 8, we aim to develop a fully autonomous SDK, eliminating any dependency on SEKAI for adjustments. This is the scope of the EIC project.

Keywords: virtual worlds,data interoperability,digital twins,industrial metaverse
Advancing Pathology: AI-Driven Screening and Synthetic Educational Training in Medical Imaging Diagnostics (dxMed AI Screening)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2002000.0
EU funding (EUR): 2002000.0
Participants: 1
Project status: SIGNED

dxMed.ai is at the forefront of integrating artificiadxMed.ai is at the forefront of integrating artificial intelligence into medical diagnostics and education, focusing primarily on enhancing oncology screening. Amidst the rising global cancer rates, projected to increase 77% by 2050, dxMed.ai’s innovation aims to tackle the delays in cancer diagnosis attributed to the manual processing of biopsies and slow referral process. The existing shortage of pathologists further strains the system, emphasizing the urgent need for enhancing diagnostic workflows, including the integration of advanced screening technologies. These technologies can help alleviate workload by automating aspects of the diagnostic process, thus speeding up the detection and analysis of medical images and biopsies. Our advanced AI-driven platform functions as a digital microscope, accelerating the screening of biopsy slides with precise image analysis, capable of parallel processing 100 slides in just a few minutes, remarkably faster than conventional methods which take hours. This year, dxMed.ai will enhance its pathology stream with advanced screening models and introduce an educational platform for medical students. We are set to revolutionize AI cancer diagnostics further by securing key certifications like CE-IVD and ISO-13485. By the next strategic milestone in 2025, we'll start developing biomarker diagnostics, with full integration expected by 2026, which will enable personalized treatment plans, improving patient outcomes through targeted therapies based on individual biomarker profiles. Our dynamic team, led by visionary founders and supported by experts across various domains of healthcare and technology, is committed to pushing the boundaries of AI in healthcare, fostering a culture of innovation, collaboration, and equity. This initiative addresses the immediate needs in cancer diagnostics and sets the stage for long-term leadership in AI-driven healthcare solutions on a global scale.

Keywords: pathology screening process
From fragments to high affinity binders interfacing integrated structural biology, medicinal chemistry and artificial intelligence (Fragment-Screen)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Technology and infrastructures
Action type: Research and Innovation actions
Countries involved: United Kingdom,France,Germany,Portugal,Denmark,Latvia,Switzerland,Italy,Spain,Czechia,Netherlands
Call: R&D for the next generation of scientific instrumentation, tools and methods (HORIZON-INFRA-2022-TECH-01, 2022)
Start date: 2023-02-01
End date: 2027-01-31
Duration (months): 48.0
Total project cost (EUR): 8265079.64
EU funding (EUR): 8265079.64
Participants: 26
Project status: SIGNED

Fragment-Screen will develop innovative instrumentation, workflows and experimental and computational methodologies for fragment-based drug discovery (FBDD) enabling access to early phase structure-based drug discovery for all biological targets and for scientists both in industry and academia. The established workflows will use structural biology insights and associated data to feed artificial intelligence (AI) methodology to guide medicinal chemistry in drug development. Fragment-Screen brings together scientists from four ESFRI Landmark research infrastructures (RIs): ESRF (the European synchrotron) and the distributed RIs EU-OPENSCREEN ERIC (medicinal chemistry), ELIXIR (data resources for life science) under the coordination of Instruct-ERIC (integrated structural biology) and seven industry partners in scientific instrumentation and computational and AI sectors including SMEs to remove crucial bottlenecks in early phase drug discovery. The new instrumentation and workflows will be available at European RIs, while the new instruments will be commercialised to increase the technological competitiveness of European industry in drug design and the attractiveness of structural biology RIs for the pharmaceutical and biotech sectors. Fragment-Screen will implement open science approaches in early drug discovery to maximise the impact of screening campaigns. Generated data will be made accessible so that iterative cycles applying AI will improve response times for drug discovery. We will create a framework for the objective and independent evaluation of AI in drug design to identify critical developments in this thriving research field. Methodologies for rigorous cross-validation will be established through demonstrator and pilot studies and results will be disseminated to the large scientific communities affiliated to the European RIs and beyond.

Keywords: fragment screening structural biology drug design artificial intelligence fair federated medicinal chemistry
500 million years of ocean pH and atmospheric CO2 (CarbonDIOs)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Earth System Science
Panel description: Physical geography, geo logy, geophysics, atmospheric sciences, oceanography, climatology, cryology, ecology, global environmental change, biogeochemical cycles, natural resources management
Countries involved: United Kingdom
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-09-01
End date: 2031-08-31
Duration (months): 60.0
Total project cost (EUR): 2497282.0
EU funding (EUR): 2497282.0
Participants: 1
Project status: SIGNED

CO2 is an important greenhouse gas and building block for life. It plays a major role in regulating Earth's environment, maintaining planetary habitability, and influencing both ocean acidity and global climate. Anthropogenic carbon emissions have raised CO2 levels to their current concentration of 420 ppm, last seen 3 million years ago. Is this high? Was Pre-Industrial CO2 low? If we want to place CO2 changes in context and understand how Earth’s environment and climate will respond to changing CO2, we need to look into Earth’s geological past. My project provides a novel way to reconstruct ocean pH and atmospheric CO2 over the last 500 million years, from the dawn of complex multi-cellular life. This will permit us to quantify pH and CO2 during key periods of Earth's history, providing fundamental insights into CO2’s past and future role in driving climate, environment and life on our planet. The CO2 molecule is acidic and freely exchanges between the ocean and atmosphere, resulting in a close coupling of ocean pH and atmospheric CO2. If ocean pH is known, atmospheric CO2 can be reconstructed. Recent advances in geochemistry make it possible to constrain pH from the boron isotope composition (δ11B) of fossil shells. The principles of this pH-meter are well-understood and rooted in the laws of thermodynamics. However, to calculate pH from fossil δ11B, two parameters are needed: (i) knowledge of boron isotope composition of seawater (δ11Bsw) and (ii) organisms’ biological imprint on δ11B (‘vital effects’). Here, I propose novel approaches to reconstruct past δ11Bsw from fluid inclusions and apatite, and to calibrate vital effects on ‘living fossils’. Armed with this knowledge, and aided by advanced robotics and computation, I will create an iconic 500-million-year record of ocean pH and atmospheric CO2 from fossil brachiopods. This will provide a step change in our understanding of CO2 and its role in Earth’s climate and habitability, past, present and future.

Keywords: co2,boron,palaeoceanography,seawater chemistry,biominerals,brachiopods
Cell identity reprogramming via ONECUT factors (CELLIDRECUT)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-02-01
End date: 2025-01-31
Duration (months): 24.0
Total project cost (EUR): 181152.96
EU funding (EUR): 181152.96
Participants: 1
Project status: CLOSED

Neuronal loss is at the core of cognitive and functional failures of both acute brain injuries and neurodegenerative diseases. Direct neuronal reprogramming of local glial cells is emerging as a promising approach for restorative brain therapy. However, in order to use direct glia-to-neuron reprogramming for the treatment of neuronal loss we still need to address a number of challenges, namely reliable and long-term conversion into the desired neuron subtype. In this proposal we aim to generate specific neuronal subtypes using novel fate determinants in glia-to-neuron reprogramming, and to provide a detailed molecular analysis of the newly generated neurons over time. Our data indicate that ONECUT factors may represent excellent novel candidates for astrocyte reprogramming into neuronal fates. To address this possibility, in this proposal we will focus on the thalamocortical system, which represents the main input to the neocortex and it is essential to cortical processing. We hypothesize that the innovative combination of nuclei specific thalamic factors with ONECUT factors could reveal new avenues for the direct reprogramming of astrocytes into thalamic neurons of specific sensory modalities and may inform future strategies for brain repair. Here, we have unique expertise and molecular tools at hand that will allow us to reprogram astrocytes into specific neuron types in vitro and in vivo. Moreover, as our ultimate goal is to reprogram astrocytes to recover neuronal loss, we will test whether astrocytes from a sensory deprived thalamus can be reprogrammed. By using state-of-the-art techniques such as 3D light-sheet microscopy, calcium imaging and transcriptomic analysis, we will determine the fidelity and functionality of the newly generated neurons. This approach will offer us unparalleled advantages for the discovery of novel reprogramming combinations and address important questions about reliable and long-term conversion into the desired neuron type.
Privacy Aware and Privacy Preserving Distributed and Robust Machine Learning for Medical Applications (PAROMA-MED)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Increased Cybersecurity
Action type: Research and Innovation actions
Countries involved: Germany,Italy,France,Belgium,Greece
Call: Scalable privacy-preserving technologies for cross-border federated computation in Europe involving personal data (HORIZON-CL3-2021-CS-01, 2021)
Start date: 2022-07-01
End date: 2025-06-30
Duration (months): 36.0
Total project cost (EUR): 4280497.5
EU funding (EUR): 4280497.5
Participants: 10
Project status: SIGNED

PAROMA-MED will develop, validate and evaluate a platform - based hybrid-cloud delivery framework for privacy- and security- assured services and applications in federative cross-border environments. To this purpose, the project will develop new architectures, technologies, tools and services to support: - automatic attestation of federation partners - privacy- and security - by-design, integrating standard compliance and performance / QoS requirements into a policy framework - consumers with their rights for opt-in / opt-out consent, portability and right to be forgotten requests, as well as transparency in access to their private-data. - federative Identity and Access Management, based on Zero Trust principles, continuous risk assessment and on confidentiality, integrity and authenticity insurance - privacy-preserving and trusted data - storage and - processing in federative environments - flexible and secure access over the Internet to private-data and service resources - AI / ML by-design, integrating platform services to be used by application developers for data-intensive applications - Zero Touch deployment and automatic life-cycle management of services and applications - managed Privacy and Security operations for automated policy enforcement and cyberthreat detection and mitigation Efficiency and scalability will be insured by the implementation of cloud-native solutions, while future adoption and further development is insured by open-source implementations. The project will validate and evaluate the PAROMA-MED framework by developing of a comprehensive Use Case with real users in the Healthcare sector. The project will create impact on the application- creation and delivery ecosystem (including standardization and legal stakeholders), on society and environment and manage the impact via dedicated activities and communication channels.

Keywords: federative learning,cryptography,edge,micro services,virtualized network functions